{"id":6717,"date":"2020-04-27T09:28:52","date_gmt":"2020-04-27T09:28:52","guid":{"rendered":"https:\/\/zuviuslifesciences.in\/old\/?post_type=product&p=6717"},"modified":"2020-07-20T07:43:45","modified_gmt":"2020-07-20T07:43:45","slug":"zolon-inj","status":"publish","type":"product","link":"https:\/\/zuviuslifesciences.in\/old\/product\/zolon-inj\/","title":{"rendered":"Zolon Inj"},"content":{"rendered":"

[vc_row][vc_column][vc_tta_tour color=”peacoc” active_section=”1″][vc_tta_section title=”Composition” tab_id=”1593254935288-a6c1025d-1fe9″][vc_column_text]Zolon 50 & 100 – Aqueous Injection\u00a0<\/strong><\/p>\n

(25 ml & 50 ml Vial)
\nEach ml contains:<\/p>\n

Oxaliplatin BP\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u20262 mg
\nZolon 150<\/strong><\/p>\n

Each ml contains:
\nOxaliplatin BP\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026\u2026..5 mg[\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Description” tab_id=”1584624217032-a15849ed-97bb”][vc_column_text]Oxalipaltin a cell cycle \u2013phase monspecific antineoplastic drugs belongs to a new class of platinum agent that contains a platinum atom complexed with oxalate and diaminocyclothexane (DACH.)<\/p>\n

Chemical Structure<\/p>\n

\"Zolon\"<\/p>\n

Chemically Oxaliplatin is trans -I \u2013 diaminocyclothexane oxatatoplatinum or cis \u2013(oxalate(trans \u2013(1.2, -diamino-cyclothexane) platinum (III) . The empirical formula of Oxaliplatin is C\u2082H4 N2 O4 Pt. The molecular weight of Oxaliplatin is 397.30. Oxaliplatin is slightly soluble in water and methanol , and insoluble in ehanol.[\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Mechanism of Action \/ Pharmcodynamics” tab_id=”1584624217050-ebb8ae5e-43a6″][vc_column_text]The exact mechanism of action of Oxaliplatin is not known. The mechanism of action of Oxaliplatin is probably similar to that of cisplatin. Oxaliplatin forms reactive platinum complexes that are believed to inhbit DNA synthesis by forming intrastrand cross-linking of DNA molecules. Oxaliplatin is not cross resistant to cisplatin or carboplatin. Probably due to the DACH group and resistance to DNA mismatch repair Oxaliplatin is a radiation sensitizing agent.[\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Pharmacokinetics” tab_id=”1584624459062-96fb7e5b-0e23″][vc_column_text]After intravenous distribution. Oxalipaltin is mainly accumulated in erythrocytes and dose not diffuse in to the plasma 85-88 % of platinum is protein bound in the first 5 hours after administration. Oxaliplatin undergoes rapid nonezymatic biotransformation to reactive platinum complexes. The active metabolites of oxaliplatin are DACH platinum species. Oxaliplatin is excreted mainly by renal excretion. Approximately 50% of the administered dose is excreted in the urine within the first 3 days. Fecal excretion is approximately 0.5%per day and reaches 5% of the total dose by day 11. The terminal half \u2013life of ultra filterable platinum (Oxaliplatin and free Oxaliplatin metabolites) is 283\u00b1 19 hrs. The platinum elimination from the erythrocytes takes about 48 days[\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Indications” tab_id=”1584624839401-59481bbb-bdc7″][vc_column_text]Oxaliplatin is indicated in the treatment of metastatic colorectal cancers after failure of treatment of fluoropyrimidines , alone by monochemotherapy or along with fluoropyrimidines.[\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Dosage & Administration” tab_id=”1584625017135-3ffdd9c5-1bd6″][vc_column_text]Colorectal Cancer In Adults<\/strong><\/p>\n

\n
    \n
  • \n
      \n
    • As single agent:<\/li>\n
    • When used alone, the recommended dose of Oxaliplatin is 130mg\/m2 \u00a0as a continuous intravenous infusion over 2 to 6 hours. The dose may be repeated at an interval of 3 weeks.<\/li>\n
    • In combination therapy:<\/li>\n
    • IV : On day 1 : administer oxaliplatin 85 mg\/m2 concurrently with leucovorin 200mg\/m2 (in separate containers using a Y line) by IV infusion over 2 hours. Then administer fluorouracil 400mg\/m2 by IV injection over 2 to 4 minutes, followed by fluorouracil 500mg\/m2 by IV infusion over 22 hours<\/li>\n
    • On day 2 \u2013 administer leucovorin 200mg\/m2 by IV infusion over 2 hours. Then administer fluorouracil 400 mg\/m2 by IV injection over 2 to 4 minutes, followed by fluorouracil 600 mg\/m2 by IV infusion over 22 hours. Repeat regimen at intervals of 2 weeks<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n

      Dosage adjustment in toxicity<\/strong><\/p>\n\n\n\n\n\n\n
      Symptom<\/th>\nOxaliplatin dose<\/th>\nFluorouracil & Leucovorin<\/th>\n<\/tr>\n
      Peripheral neuropathy<\/td>\nAdminister over 6 hours<\/td>\nNo adjustment required<\/td>\n<\/tr>\n
      Persistent grade 2 neurosensory effect<\/td>\nReduce dose by 25% (i.e. 65mg\/m)<\/td>\nNo adjustment required<\/td>\n<\/tr>\n
      In patients who recover from grade 3 or 4 GI toxicity grade 4 neutropenia or grade 3 or 4 thrombocytopenia<\/td>\nReduce dose by 25% ( i.e. 65mg\/m)<\/td>\nReduce fluorouracil dose by 20% (i.e. to 300mg\/m2 by IV injection over 2 to 4 minutes and 500 mg\/m2 by IV infusion over 22 hours<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
        \n
      • Do not administer next dose until neutrophilcourt \u00a0> 1500\/mm2 and platelet count > 75.000m2<\/li>\n<\/ul>\n<\/div>\n

        Renal Impairment:<\/strong><\/p>\n

        In patients with impaired renal function, observed caution<\/p>\n

        MONITORING PARAMETERS:<\/strong><\/p>\n

        Assess the patients for differential WBC count, hemoglobin, platelet count, and ALT, AST, bilirubin, and creatinine level before each Oxaliplatin cycle.[\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Warnings” tab_id=”1587978464677-818e3c8a-8b36″][vc_column_text]<\/p>\n

          \n
        • in the use of cancer chemotherapeutic agents.<\/li>\n
        • Aluminum has been reported to cause degradation of platinum compounds and hence needles of intravenous administration sets containing aluminum parts that may come in contact with oxaliplatin should not be used for the preparation or mixing of the drugs.<\/li>\n
        • Oxaliplatin should not be administered undiluted. Dilute with 5% Dextrose infusion.<\/li>\n
        • Oxaliplatin is incompatible in solution with alkaline medications or media and hence it is advised that oxaliplatin should never be diluted with Sodium Chloride\/Chloride \u2013 containing infusion solutions.<\/li>\n
        • Oxaliplatin has been found to be mutagenic in mammalian in vitro mutation chromosome test. Although carcinogenic studies have not been done. Oxaliplatin is considered a probable carcinogen.<\/li>\n
        • Oxaliplatin is embryotoxic and fetotoxic in rates. Oxaliplatin may cause fetal harm when administered to pregnant women. The patient should be apprised of the potential hazard to the fetus and potential risk for loss of the pregnancy if there is exposure to Oxaliplatin during pregnancy.<\/li>\n<\/ul>\n

          [\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Precautions” tab_id=”1587978466341-e08f7517-4cca”][vc_column_text]<\/p>\n

            \n
          • Oxaliplatin should not be mixed with any other medication and it should not be administered simultaneously by the same infusion line.<\/li>\n
          • \u00a0Caution is recommended while administering Oxaliplatin to patients with known hypersensitivity to other platinum agents.<\/li>\n
          • It is known whether oxaliplatin is excreted in human milk or not caution should be exercised when oxaliplatin is administered to a nursing woman as many drugs are excreted in human milk.<\/li>\n
          • Inspect the solution visually for particulate matter and discoloration prior to administration.<\/li>\n<\/ul>\n

            [\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Adverse Reactions (Side Effects)” tab_id=”1587978467943-190d6254-3b32″][vc_column_text]Commonly occurring adverse effect of Oxaliplatin are:<\/p>\n

            \n
              \n
            • Sensory neuropathy<\/li>\n
            • Anemia<\/li>\n
            • Fever<\/li>\n
            • Nausea & Vomiting<\/li>\n
            • Liver function abnormalities<\/li>\n
            • Infections<\/li>\n
            • Alopecia<\/li>\n
            • Pharyngolaryngeal dysesthesia<\/li>\n<\/ul>\n<\/div>\n

              Other side effects that become more pronounced when used in combination with flurouracil and leucovorin are:<\/p>\n

              \n
                \n
              • Neutropenia<\/li>\n
              • Thrombocytopenia<\/li>\n
              • Diarrhorea<\/li>\n
              • Mucostitis<\/li>\n<\/ul>\n<\/div>\n

                [\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Drug Interactions” tab_id=”1587978788920-a652582e-1377″][vc_column_text]Oxaliplatin induces irinotecan related cholinergic syndrome by potentiating irinotecan inhibition of acetylcholinesterase. Oxaliplatin has no influence on flurouracil and topotecan pharmacokinetics. Preclinical studies have shown oxaliplatin to be synergetic with flurourocil and SN-38, the active metabolite of irinotican.<\/p>\n

                There are no other studies documenting any major intractions of oxalipaltin with other drugs.[\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Overdose & Contradiction” tab_id=”1587978790937-0b0c9a9f-418f”][vc_column_text]There is no know antidote for Oxaliplatin overdosage in general supportive care and frequent monitoring of vital signs should be administered<\/p>\n

                CONTRAINDICATIONS<\/strong><\/p>\n

                Oxaliplatin is contraindicated in patient with<\/p>\n

                \n
                  \n
                • History of severe allergy to the drug<\/li>\n
                • Severe Pre-existing peripheral neuropathy<\/li>\n
                • Severe rena dysfunction (Crcl<30ml\/min)<\/li>\n
                • Pregnancy and Breast feeding<\/li>\n<\/ul>\n<\/div>\n

                  [\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Storage” tab_id=”1587978793604-7c71901c-62cf”][vc_column_text]To be stored at a temperature below 25\u1d3cC. Protect from light. Do not freeze[\/vc_column_text][\/vc_tta_section][vc_tta_section title=”Presentation” tab_id=”1587978938510-bff2f998-3197″][vc_column_text]Zolon as 25ml vial- containing 50 mg of oxaliplatin
                  \nZolon as 50ml vial- containing 100 mg of oxaliplatin.
                  \nZolon as 30ml vial- containing 50 mg of oxaliplatin.[\/vc_column_text][\/vc_tta_section][\/vc_tta_tour][\/vc_column][\/vc_row]<\/p>\n","protected":false},"excerpt":{"rendered":"

                  Oxaliplatin Inj – 150MG 100MG 50MG<\/strong><\/p>\n

                  Oxaliplatin is indicated in the treatment of metastatic colorectal cancers after the failure of treatment of fluoropyrimidines, alone by monochemotherapy or along with fluoropyrimidines.<\/p>\n

                   <\/p>\n","protected":false},"featured_media":7730,"template":"","meta":{"spay_email":""},"product_cat":[66,67],"product_tag":[175,174],"jetpack-related-posts":[{"id":6691,"url":"https:\/\/zuviuslifesciences.in\/old\/product\/zuvidox-inj\/","url_meta":{"origin":6717,"position":0},"title":"Zuvidox Inj","date":"April 25, 2020","format":false,"excerpt":"Doxorubicin Inj - 10MG, 50MG Doxorubicin is indicated in the treatment of acute leukemia, soft tissue, and bone sarcomas, breast cancer, ovarian cancer, Hodgkin's, and non-Hodgkin\u2019s lymphomas, small cell lung cancer, gastric carcinoma, and bladder carcinoma.","rel":"","context":"Similar post","img":{"alt_text":"","src":"https:\/\/i0.wp.com\/zuviuslifesciences.in\/old\/wp-content\/uploads\/2020\/04\/Zuvidox-Group-1_1000-x-1000px.jpg?fit=1000%2C1000&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":6743,"url":"https:\/\/zuviuslifesciences.in\/old\/product\/z-cristin-inj\/","url_meta":{"origin":6717,"position":1},"title":"Z-cristin Inj","date":"April 27, 2020","format":false,"excerpt":"Vincristine Inj - 1MG Vincristine sulfate injection is indicated in acute leukemia. Vincristine sulfate injection has also been shown to be useful in combination with other oncolytic agents in Hodgkin\u2019s disease, non\u2013Hodgkin\u2019s malignant lymphomas, rhabdomyosarcoma, neuroblastoma, and Wilms\u2019 tumor.","rel":"","context":"Similar post","img":{"alt_text":"Z-cristin","src":"https:\/\/i0.wp.com\/zuviuslifesciences.in\/old\/wp-content\/uploads\/2020\/04\/image-44.jpg?fit=615%2C385&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":6710,"url":"https:\/\/zuviuslifesciences.in\/old\/product\/zeflo-inj\/","url_meta":{"origin":6717,"position":2},"title":"Zeflo Inj","date":"April 27, 2020","format":false,"excerpt":"Fluorouracil Inj - 250MG, 500MG Fluorouracil is indicated in the palliative treatment of carcinoma of the colon, rectum, breast, stomach, and pancreas. \u00a0 \u00a0","rel":"","context":"Similar post","img":{"alt_text":"Zeflo 500mg_1_1000 x 1000px","src":"https:\/\/i0.wp.com\/zuviuslifesciences.in\/old\/wp-content\/uploads\/2020\/04\/Zeflo-500mg_1_1000-x-1000px.jpg?fit=1000%2C1000&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":6748,"url":"https:\/\/zuviuslifesciences.in\/old\/product\/cytraz-inj\/","url_meta":{"origin":6717,"position":3},"title":"Cytraz Inj","date":"April 27, 2020","format":false,"excerpt":"Cytarabine inj - 100MG, 500MG, 1000MG Cytarabine in combination with other approved anticancer drugs is indicated for remission induction in acute non-lymphocytic leukemia of adults and children. It has also been found useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. Intrathecal administration\u2026","rel":"","context":"Similar post","img":{"alt_text":"","src":"https:\/\/i0.wp.com\/zuviuslifesciences.in\/old\/wp-content\/uploads\/2020\/04\/Cytraz-1mg_1_1000-x-1000px.jpg?fit=1000%2C1000&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":6689,"url":"https:\/\/zuviuslifesciences.in\/old\/product\/dazine-inj\/","url_meta":{"origin":6717,"position":4},"title":"Dazine Inj","date":"April 25, 2020","format":false,"excerpt":"Dacarbazine Inj - 200 MG, 500MG Dazine is indicated in the treatment of metastatic malignant melanoma, Hodgkin' disease as a secondary-line therapy when used in combination with other effective agents, neuroblastoma, soft-tissue sarcoma including leiomyosarcoma","rel":"","context":"Similar post","img":{"alt_text":"Dazine 200mg & 500mg_3_000 x 1000px","src":"https:\/\/i0.wp.com\/zuviuslifesciences.in\/old\/wp-content\/uploads\/2020\/04\/Dazine-200mg-500mg_3_000-x-1000px.jpg?fit=1000%2C1000&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]},{"id":6733,"url":"https:\/\/zuviuslifesciences.in\/old\/product\/zetabin-inj\/","url_meta":{"origin":6717,"position":5},"title":"Zetabin Inj","date":"April 27, 2020","format":false,"excerpt":"Gemcitabine Inj - 1GM, 1.4GM, 200MG First-line treatment of locally advanced or metastatic Pancreatic adenocarcinoma in patients previously treated with 5-fluorouracil; first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC); Treatment of advanced ovarian cancer that has relapsed at least 6 mo after completion of platinum-based therapy;\u2026","rel":"","context":"Similar post","img":{"alt_text":"","src":"https:\/\/i0.wp.com\/zuviuslifesciences.in\/old\/wp-content\/uploads\/2020\/04\/Zetabin-Group-1_1000-x-1000px.jpg?fit=1000%2C1000&ssl=1&resize=350%2C200","width":350,"height":200},"classes":[]}],"_links":{"self":[{"href":"https:\/\/zuviuslifesciences.in\/old\/wp-json\/wp\/v2\/product\/6717"}],"collection":[{"href":"https:\/\/zuviuslifesciences.in\/old\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/zuviuslifesciences.in\/old\/wp-json\/wp\/v2\/types\/product"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/zuviuslifesciences.in\/old\/wp-json\/wp\/v2\/media\/7730"}],"wp:attachment":[{"href":"https:\/\/zuviuslifesciences.in\/old\/wp-json\/wp\/v2\/media?parent=6717"}],"wp:term":[{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/zuviuslifesciences.in\/old\/wp-json\/wp\/v2\/product_cat?post=6717"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/zuviuslifesciences.in\/old\/wp-json\/wp\/v2\/product_tag?post=6717"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}